Use of analgesics in France, following dextropropoxyphene withdrawal
Abstract Background In 2009, the European Medicines Agency recommended withdrawal of dextropropoxyphene (DXP); in March 2011 it was withdrawn from the market in France. Up until that time the combination dextropropoxyphene-paracetamol (DXP/PC) was widely used for analgesia. At withdrawal, French reg...
Main Authors: | E. Van Ganse, M. Belhassen, M. Ginoux, E. Chrétien, C. Cornu, C. Ecoffey, F. Aubrun |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-04-01
|
Series: | BMC Health Services Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12913-018-3058-1 |
Similar Items
-
Use of dextropropoxyphene in modern therapeutics : Efficacy, dependence liability and toxicity of dextropropoxyphene/paracetamol combinations with special reference to epidemiology of self-poisoning by analgesic drugs
by: Dwyer, P. S.
Published: (1988) -
The efficacy of Antipyretic Analgesics administration intravenously for Preventing Rocuronium-Associated Pain/Withdrawal Response: a systematic review and meta-analysis
by: Jia Wang, et al.
Published: (2020-04-01) -
Shortening Anesthesia Duration does not Affect Severity of Withdrawal Syndrome in Patients Undergoing Ultra Rapid Opioid Detoxification
by: Shoaleh Shami, et al.
Published: (2010-02-01) -
Shortening Anesthesia Duration does not Affect Severity of Withdrawal Syndrome in Patients Undergoing Ultra Rapid Opioid Detoxification
by: Karim Nasseri, et al.
Published: (2010-02-01) -
Caffeine as an opioid analgesic adjuvant in fibromyalgia
by: Scott JR, et al.
Published: (2017-07-01)